U.S. market Closed. Opens in 1 day 9 hours 2 minutes

BOLT | Bolt Biotherapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue7.88M5.73M1.26M231.00K215.00KN/A
Cost of Revenue1.88M4.89M3.67M40.36M26.00M302.00K
Gross Profit5.99M838.00K-2.41M-40.13M-25.79M-302.00K
Operating Expenses84.07M96.05M94.05M49.41M31.18M11.63M
Selling, General & Admin22.53M22.93M18.39M9.06M5.18M2.21M
Research & Development61.54M73.12M75.66M40.36M26.00M9.42M
Other Operating ExpensesN/AN/A-6.08M-11.74M-42.00K-153.00K
Operating Income-76.20M-90.32M-92.79M-49.18M-30.97M-11.63M
Other Expenses / Income7.00M2.22M-5.80M-11.55M482.00K40.00K
Before Tax Income-69.20M-88.10M-98.59M-60.73M-30.49M-11.59M
Income Tax ExpensesN/A-2.22M5.80M11.55M-482.00K40.00K
Net Income-69.20M-85.88M-104.39M-72.27M-30.00M-11.59M
Interest ExpensesN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding37.81M37.36M37.40M36.25M35.10M9.42M
Diluted Shares Outstanding37.81M37.36M37.40M36.25M35.10M9.42M
EBITDA-74.34M-88.66M-91.59M-48.57M-30.63M-11.33M
EBITDA Margin-943.91%-1,547.48%-7,269.44%-21,026.41%-14,248.37%0.00%
EBIT-69.20M-88.10M-98.59M-60.73M-30.49M-11.55M
EBIT Margin-878.58%-1,537.76%-7,824.68%-26,289.18%-14,180.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙